| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xue Zhang, Min-Jun Liao, Li-Ying Ren, Wan-Ying Qin, Shao-Wei Mu, Shao-Ping She, Ran Fei, Xu Cong, Yuan-Ping Zhou, Dong-Bo Chen and Hong-Song Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Key Sci-Tech Special Project of China |
2018ZX10302207 |
| Beijing Nova Program |
20250484965 |
| Beijing Natural Science Foundation |
7222191 |
| Beijing Natural Science Foundation |
7244426 |
| Fundamental Research Funds for the Central Universities, Peking University |
PKU2024XGK005 |
| Peking University Medicine Seed Fund for Interdisciplinary Research |
BMU2021MX007 |
| Peking University Medicine Seed Fund for Interdisciplinary Research |
BMU2022MX001 |
| Fundamental Research Funds for the Central Universities, Peking University People’s Hospital Scientific Research Development Funds |
RDX2020-06 |
| Fundamental Research Funds for the Central Universities, Peking University People’s Hospital Scientific Research Development Funds |
RDJ2022-14 |
| Qi-Min Project |
|
|
| Corresponding Author |
Hong-Song Chen, Professor, Peking University People’s Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People’s Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing 100044, China. chenhongsong2999@163.com |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Sintilimab; Lenvatinib; AADN score |
| Core Tip |
This multicenter study developed and validated a novel AADN score to predict survival in patients with unresectable hepatocellular carcinoma treated with triple therapy (transarterial chemoembolization, sintilimab, and lenvatinib). AADN score = 0.947 × alpha-fetoprotein (ng/mL) (0: ≤ 100; 1: > 100) + 0.804 × alkaline phosphatase (U/L) (0: ≤ 120; 1: > 120) + 1.075 × direct bilirubin (μmol/L) (0: ≤ 7.3; 1: > 7.3) + 1.14 × neutrophil to lymphocyte ratio (0: ≤ 2.5; 1: > 2.5). The AADN score effectively stratified patients into distinct low-risk, intermediate-risk, and high-risk groups with significantly different overall and progression-free survival outcomes, demonstrating high predictive accuracy. This tool provides a practical basis for prognostic assessment and individualized treatment decision-making in this patient population. |
| Publish Date |
2025-12-27 02:50 |
| Citation |
Zhang X, Liao MJ, Ren LY, Qin WY, Mu SW, She SP, Fei R, Cong X, Zhou YP, Chen DB, Chen HS. AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma. World J Gastroenterol 2025; 31(48): 113856 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i48/113856.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i48.113856 |
